

Dunbar Ivy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8397837/publications.pdf>

Version: 2024-02-01

198
papers

9,258
citations

53794

45
h-index

45317

90
g-index

209
all docs

209
docs citations

209
times ranked

4763
citing authors

#	ARTICLE	IF	CITATIONS
1	Abnormal flow conduction through pulmonary arteries is associated with right ventricular volume and function in patients with repaired tetralogy of Fallot: does flow quality affect afterload?. <i>European Radiology</i> , 2023, 33, 302-311.	4.5	4
2	Characterisation of paediatric pulmonary hypertensive vascular disease from the PPHNet Registry. <i>European Respiratory Journal</i> , 2022, 59, 2003337.	6.7	43
3	Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine. <i>Annals of the American Thoracic Society</i> , 2022, 19, 227-237.	3.2	16
4	Biomarkers of Pulmonary Hypertension Are Altered in Children with Down Syndrome and Pulmonary Hypertension. <i>Journal of Pediatrics</i> , 2022, 241, 68-76.e3.	1.8	3
5	Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience. <i>Pediatric Pulmonology</i> , 2022, 57, 724-733.	2.0	7
6	Pulmonary Hypertension in the Population with Down Syndrome. <i>Cardiology and Therapy</i> , 2022, 11, 33-47.	2.6	11
7	Technical Feasibility on the Use of Optical Coherence Tomography in the Evaluation of Pediatric Pulmonary Venous Stenosis. <i>Pediatric Cardiology</i> , 2022, , 1.	1.3	4
8	Hepatoma-derived growth factor is associated with pulmonary vascular remodeling and PAH disease severity and survival. <i>Pulmonary Circulation</i> , 2022, 12, e12007.	1.7	1
9	Repolarization Dispersion Is Associated With Diastolic Electromechanical Discoordination in Children With Pulmonary Arterial Hypertension. <i>Journal of the American Heart Association</i> , 2022, 11, e024787.	3.7	3
10	High-Altitude Pulmonary Edema in Colorado Children: A Cross-Sectional Survey and Retrospective Review. <i>High Altitude Medicine and Biology</i> , 2022, 23, 119-124.	0.9	2
11	Pulmonary hypertension in children with Down syndrome. <i>Pediatric Pulmonology</i> , 2021, 56, 621-629.	2.0	29
12	Obesity in Pulmonary Arterial Hypertension. The Pulmonary Hypertension Association Registry. <i>Annals of the American Thoracic Society</i> , 2021, 18, 229-237.	3.2	18
13	Pulmonary vein stenosis: Treatment and challenges. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 2169-2176.	0.8	33
14	Prediction of Health-related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 761-764.	5.6	12
15	Patients with Fontan circulation have abnormal aortic wave propagation patterns: A wave intensity analysis study. <i>International Journal of Cardiology</i> , 2021, 322, 158-167.	1.7	9
16	Right ventricular area strain from 3-dimensional echocardiography: Mechanistic insight of right ventricular dysfunction in pediatric pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 138-148.	0.6	13
17	Practice patterns of pulmonary hypertension secondary to left heart disease among pediatric pulmonary hypertension providers. <i>Pulmonary Circulation</i> , 2021, 11, 1-8.	1.7	3
18	High-degree Norwood neo-aortic tapering is associated with abnormal flow conduction and elevated flow-mediated energy loss. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 162, 1791-1804.	0.8	13

#	ARTICLE	IF	CITATIONS
19	Short-Term Effects of Inhaled Nitric Oxide on Right Ventricular Flow Hemodynamics by 4-Dimensional Flow Magnetic Resonance Imaging in Children With Pulmonary Arterial Hypertension. <i>Journal of the American Heart Association</i> , 2021, 10, e020548.	3.7	12
20	Longitudinal assessment of right atrial conduit fraction provides additional insight to predict adverse events in pediatric pulmonary hypertension. <i>International Journal of Cardiology</i> , 2021, 329, 242-245.	1.7	5
21	Abnormal pulmonary flow is associated with impaired right ventricular coupling in patients with COPD. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 3039-3048.	1.5	5
22	Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, double-blind placebo-controlled study. <i>Pulmonary Circulation</i> , 2021, 11, 1-8.	1.7	10
23	Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry. <i>Pulmonary Circulation</i> , 2021, 11, 1-10.	1.7	17
24	Pulmonary arterial banding in mice may be a suitable model for studies on ventricular mechanics in pediatric pulmonary arterial hypertension. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021, 23, 66.	3.3	3
25	Echocardiographic Changes and Long-Term Clinical Outcomes in Pediatric Patients With Pulmonary Arterial Hypertension Treated With Bosentan for 72 Weeks: A Post-hoc Analysis From the FUTURE 3 Study. <i>Frontiers in Pediatrics</i> , 2021, 9, 681538.	1.9	1
26	Metalloproteinases and their inhibitors are associated with pulmonary arterial stiffness and ventricular function in pediatric pulmonary hypertension. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2021, 321, H242-H252.	3.2	11
27	ST2 Is a Biomarker of Pediatric Pulmonary Arterial Hypertension Severity and Clinical Worsening. <i>Chest</i> , 2021, 160, 297-306.	0.8	6
28	Pulmonary-to-Systemic Arterial Shunt to Treat Children With Severe Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2021, 78, 468-477.	2.8	24
29	B-PO01-103 IMMEDIATE CHANGE IN SYSTOLIC STRETCH FRACTION PREDICTS RESPONSIVENESS TO CARDIAC RESYNCHRONIZATION THERAPY IN PATIENTS WITH CONGENITAL HEART DISEASE. <i>Heart Rhythm</i> , 2021, 18, S92.	0.7	0
30	The angiostatic peptide endostatin enhances mortality risk prediction in pulmonary arterial hypertension. <i>ERJ Open Research</i> , 2021, 7, 00378-2021.	2.6	5
31	Hemodynamic and prognostic impact of the diastolic pulmonary arterial pressure in children with pulmonary arterial hypertension—a registry-based analysis. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 1037-1047.	1.7	4
32	Ventricular-vascular coupling is predictive of adverse clinical outcome in paediatric pulmonary arterial hypertension. <i>Open Heart</i> , 2021, 8, e001611.	2.3	3
33	Angiostatic Peptide, Endostatin, Predicts Severity in Pediatric Congenital Heart Disease-Associated Pulmonary Hypertension. <i>Journal of the American Heart Association</i> , 2021, 10, e021409.	3.7	5
34	Update on pediatric pulmonary arterial hypertension. <i>Current Opinion in Cardiology</i> , 2021, 36, 67-79.	1.8	8
35	Monitoring and evaluation of the surgical Potts shunt physiology using 4-dimensional flow magnetic resonance imaging. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, , .	0.8	2
36	An Acute Hyperoxia Test Predicts Survival in Children with Pulmonary Hypertension Living at High Altitude. <i>High Altitude Medicine and Biology</i> , 2021, 22, 395-405.	0.9	0

#	ARTICLE	IF	CITATIONS
37	Abnormal aortic flow conduction is associated with increased viscous energy loss in patients with repaired tetralogy of Fallot. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 57, 588-595.	1.4	18
38	Increased systolic vorticity in the left ventricular outflow tract is associated with abnormal aortic flow formations in Tetralogy of Fallot. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 691-700.	1.5	13
39	Parameters of Right Ventricular Function Reveal Ventricular-Vascular Mismatch as Determined by Right Ventricular Stroke Work versus Pulmonary Vascular Resistance in Children with Pulmonary Hypertension. <i>Journal of the American Society of Echocardiography</i> , 2020, 33, 218-225.	2.8	12
40	Abnormal left ventricular flow organization following repair of tetralogy of Fallot. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 160, 1008-1015.	0.8	17
41	Novel measures of left ventricular electromechanical discoordination predict clinical outcomes in children with pulmonary arterial hypertension. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2020, 318, H401-H412.	3.2	18
42	Segmental Pulmonary Hypertension in Children with Congenital Heart Disease. <i>Medicina (Lithuania)</i> , 2020, 56, 492.	2.0	1
43	Update on noninvasive imaging of right ventricle dysfunction in pulmonary hypertension. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 1604-1624.	1.7	16
44	Elevated Interleukin-6 Levels Predict Clinical Worsening in Pediatric Pulmonary Arterial Hypertension. <i>Journal of Pediatrics</i> , 2020, 223, 164-169.e1.	1.8	9
45	Frequency of Reduced Left Ventricular Contractile Efficiency and Disordinated Myocardial Relaxation in Patients Aged 16 to 21 Years With Type 1 Diabetes Mellitus (from the Emerald Study). <i>American Journal of Cardiology</i> , 2020, 128, 45-53.	1.6	11
46	Pharmacokinetics of Oral Treprostinil in Children With Pulmonary Arterial Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 94-100.	1.9	3
47	Pediatric pulmonary hypertension: insulin-like growth factor-binding protein 2 is a novel marker associated with disease severity and survival. <i>Pediatric Research</i> , 2020, 88, 850-856.	2.3	6
48	Pediatric Cardiology. <i>Pediatric Clinics of North America</i> , 2020, 67, i.	1.8	0
49	Pediatric Pulmonary Arterial Hypertension. <i>Pediatric Clinics of North America</i> , 2020, 67, 903-921.	1.8	9
50	Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary Hypertension Association Registry. <i>Pulmonary Circulation</i> , 2020, 10, 1-8.	1.7	5
51	Pediatric Cardiology: From Basics to Innovation. <i>Pediatric Clinics of North America</i> , 2020, 67, xvii-xviii.	1.8	0
52	A Randomized Study of Safety and Efficacy of Two Doses of Ambrisentan to Treat Pulmonary Arterial Hypertension in Pediatric Patients Aged 8 Years up to 18 Years. <i>Journal of Pediatrics: X</i> , 2020, 5, 100055.	1.1	1
53	MicroRNA as a Biomarker in Pediatric Pulmonary Hypertension. <i>Pediatric Critical Care Medicine</i> , 2020, 21, 393-394.	0.5	0
54	Relationship Between Left Ventricular Geometry and Invasive Hemodynamics in Pediatric Pulmonary Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e009825.	2.6	39

#	ARTICLE	IF	CITATIONS
55	The left ventricle undergoes biomechanical and gene expression changes in response to increased right ventricular pressure overload. <i>Physiological Reports</i> , 2020, 8, e14347.	1.7	9
56	The Left Heart, Systemic Circulation, and Bronchopulmonary Dysplasia: Relevance to Pathophysiology and Therapeutics. <i>Journal of Pediatrics</i> , 2020, 225, 13-22.e2.	1.8	20
57	Partial occlusion of PDA in a patient with severe pulmonary hypertension using a manually fenestrated and stented muscular VSD device. <i>Progress in Pediatric Cardiology</i> , 2020, 59, 101229.	0.4	0
58	Flow profile characteristics in Fontan circulation are associated with the single ventricle dilation and function: principal component analysis study. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2020, 318, H1032-H1040.	3.2	7
59	Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 945-953.	0.6	15
60	The failing right ventricle: Where do we go from here. <i>Acta Physiologica</i> , 2020, 229, e13523.	3.8	2
61	Right Atrial Conduit Phase Emptying Predicts Risk of Adverse Events in Pediatric Pulmonary Arterial Hypertension. <i>Journal of the American Society of Echocardiography</i> , 2020, 33, 1006-1013.	2.8	8
62	Reply to Commentary: Can't flow down: More 4-dimensional flow magnetic resonance imaging studies are needed in congenital heart disease. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 160, 1019-1020.	0.8	0
63	Pediatric Pulmonary Arterial Hypertension: Evaluation and Treatment. <i>Current Treatment Options in Pediatrics</i> , 2020, 6, 12-28.	0.6	1
64	Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension. <i>Chest</i> , 2020, 157, 1606-1616.	0.8	20
65	Drug Treatment of Pulmonary Hypertension in Children. <i>Paediatric Drugs</i> , 2020, 22, 123-147.	3.1	21
66	Complete Atrioventricular Septal Defects. , 2020, , 173-184.		0
67	Acute Pulmonary Hypertension. , 2020, , 455-464.		0
68	Chronic Pulmonary Hypertension. , 2020, , 465-489.		0
69	Ebstein's Disease of the Tricuspid Valve. , 2020, , 405-417.		0
70	Abstract 13708: Right Ventricular Strain Comparison Between Quantification Software in Pediatric Normal and Pulmonary Hypertension Patients. <i>Circulation</i> , 2020, 142, .	1.6	0
71	Proximal pulmonary vascular stiffness as a prognostic factor in children with pulmonary arterial hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 209-217.	1.2	36
72	Treatment of pediatric pulmonary arterial hypertension: A focus on the NO-cGMP pathway. <i>Pediatric Pulmonology</i> , 2019, 54, 1516-1526.	2.0	19

#	ARTICLE	IF	CITATIONS
73	Transvenous implantation of the Occlutech Atrial Flow Regulator: Preliminary results from swine models. <i>Congenital Heart Disease</i> , 2019, 14, 819-831.	0.2	6
74	Right Ventricular-Arterial Coupling Ratio Derived From 3-Dimensional Echocardiography Predicts Outcomes in Pediatric Pulmonary Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e008176.	2.6	29
75	Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2019, 9, 1-8.	1.7	14
76	New Strategies for the Conduct of Clinical Trials in Pediatric Pulmonary Arterial Hypertension: Outcome of a Multistakeholder Meeting With Patients, Academia, Industry, and Regulators, Held at the European Medicines Agency on Monday, June 12, 2017. <i>Journal of the American Heart Association</i> , 2019, 8, e011306.	3.7	23
77	Acute vasoreactivity testing in pediatric idiopathic pulmonary arterial hypertension: an international survey on current practice. <i>Pulmonary Circulation</i> , 2019, 9, 1-9.	1.7	7
78	Meaningful and feasible composite clinical worsening definitions in paediatric pulmonary arterial hypertension: An analysis of the TOPP registry. <i>International Journal of Cardiology</i> , 2019, 289, 110-115.	1.7	11
79	High Altitude Pulmonary Edema in Children: A Single Referral Center Evaluation. <i>Journal of Pediatrics</i> , 2019, 210, 106-111.	1.8	12
80	Differences in pulmonary arterial flow hemodynamics between children and adults with pulmonary arterial hypertension as assessed by 4D-flow CMR studies. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2019, 316, H1091-H1104.	3.2	20
81	Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI). <i>Pulmonary Circulation</i> , 2019, 9, 1-32.	1.7	96
82	Usefulness of 4D-Flow MRI in Mapping Flow Distribution Through Failing Fontan Circulation Prior to Cardiac Intervention. <i>Pediatric Cardiology</i> , 2019, 40, 1093-1096.	1.3	12
83	Ventricular interactions and electromechanical dyssynchrony after Ross and Ross-Konno operations. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 158, 509-517.	0.8	14
84	Structural and Biomechanical Adaptations of Right Ventricular Remodeling "In Pulmonary Arterial Hypertension" Reduces Left Ventricular Rotation During Contraction: A Computational Study. <i>Journal of Biomechanical Engineering</i> , 2019, 141, .	1.3	9
85	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 227-238.	10.7	122
86	Tale of 2 Endothelin Receptor Antagonists in Eisenmenger Syndrome. <i>Circulation</i> , 2019, 139, 64-66.	1.6	6
87	Influence of aortic stiffness on ventricular function in patients with Fontan circulation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 699-707.	0.8	13
88	Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. <i>European Respiratory Journal</i> , 2019, 53, 1801916.	6.7	399
89	Serum endostatin as a genetically-influenced biomarker in PAH. , 2019, , .		1
90	Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	23

#	ARTICLE	IF	CITATIONS
91	Aortic stiffness in adolescent Turner and Marfan syndrome patients. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 54, 926-932.	1.4	15
92	Impact of different coarctation therapies on aortic stiffness: phase-contrast MRI study. <i>International Journal of Cardiovascular Imaging</i> , 2018, 34, 1459-1469.	1.5	17
93	Predictive value of presuperior cavopulmonary anastomosis cardiac catheterization at increased altitude. <i>Congenital Heart Disease</i> , 2018, 13, 311-318.	0.2	1
94	Children with kawasaki disease present elevated stiffness of great arteries: Phase-contrast MRI study. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 48, 1228-1236.	3.4	5
95	Effect of electrical dyssynchrony on left and right ventricular mechanics in children with pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 870-878.	0.6	25
96	Measuring Flow Hemodynamic Indices and Oxygen Consumption in Children with Pulmonary Hypertension: A Comparison of Catheterization and Phase-Contrast MRI. <i>Pediatric Cardiology</i> , 2018, 39, 268-274.	1.3	11
97	Right Ventricular Tissue Doppler Myocardial Performance Index in Children with Pulmonary Hypertension: Relation to Invasive Hemodynamics. <i>Pediatric Cardiology</i> , 2018, 39, 98-104.	1.3	10
98	3D echocardiographic evaluation of right ventricular function and strain: a prognostic study in paediatric pulmonary hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 1026-1033.	1.2	57
99	Reduced proximal aortic compliance and elevated wall shear stress after early repair of tetralogy of Fallot. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 156, 2239-2249.	0.8	27
100	Right Heart Failure in Pediatric Pulmonary Hypertension. , 2018, , 399-412.		1
101	Noninvasive wave intensity analysis predicts functional worsening in children with pulmonary arterial hypertension. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 315, H968-H977.	3.2	28
102	Diagnosis, Evaluation and Treatment of Pulmonary Arterial Hypertension in Children. <i>Children</i> , 2018, 5, 44.	1.5	15
103	Clinical Characteristics and Risk Factors for Developing Pulmonary Hypertension in Children with Down Syndrome. <i>Journal of Pediatrics</i> , 2018, 202, 212-219.e2.	1.8	81
104	Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease. <i>Genome Medicine</i> , 2018, 10, 56.	8.2	112
105	Tricuspid annular plane systolic excursion is preserved in young patients with pulmonary hypertension except when associated with repaired congenital heart disease. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 459-466.	1.2	14
106	Apparent Aortic Stiffness in Children With Pulmonary Arterial Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	2.6	29
107	A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1734-1744.	2.4	24
108	Pulmonary arterial hypertension in children after neonatal arterial switch operation. <i>Heart</i> , 2017, 103, 1244-1249.	2.9	23

#	ARTICLE	IF	CITATIONS
109	Evaluation and Management of Pulmonary Hypertension in Children with Bronchopulmonary Dysplasia. <i>Journal of Pediatrics</i> , 2017, 188, 24-34.e1.	1.8	175
110	Altered Peripheral Blood Myeloid Cell Subpopulations in Children With Down Syndrome and Pulmonary Hypertension. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, 158-159.	0.6	3
111	Right Atrial Deformation in Predicting Outcomes in Pediatric Pulmonary Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	2.6	41
112	2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil. <i>Journal of the American College of Cardiology</i> , 2017, 70, 495-503.	2.8	2
113	Evaluation of predictive models for six minute walk test among children with pulmonary hypertension. <i>International Journal of Cardiology</i> , 2017, 227, 393-398.	1.7	6
114	Pulmonary Arterial Capacitance Index Is a Strong Predictor for Adverse Outcome in Children with Idiopathic and Heritable Pulmonary Arterial Hypertension. <i>Journal of Pediatrics</i> , 2017, 180, 75-79.e2.	1.8	23
115	The Anesthetic Challenges of Lung Biopsy—Associated Intrathoracic Hemorrhage in a Child With Suprasystemic Pulmonary Hypertension. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2017, 21, 172-177.	1.0	1
116	Circulating miRNAs in Pediatric Pulmonary Hypertension Show Promise as Biomarkers of Vascular Function. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-11.	4.0	16
117	Pediatric Cardiac Intensive Care Society 2014 Consensus Statement. <i>Pediatric Critical Care Medicine</i> , 2016, 17, S89-S100.	0.5	19
118	Three-dimensional Echocardiography of Right Ventricular Function Correlates with Severity of Pediatric Pulmonary Hypertension. <i>Congenital Heart Disease</i> , 2016, 11, 562-569.	0.2	27
119	A Zero-Dimensional Model and Protocol for Simulating Patient-Specific Pulmonary Hemodynamics From Limited Clinical Data. <i>Journal of Biomechanical Engineering</i> , 2016, 138, .	1.3	7
120	Impact of Pulmonary Hemodynamics and Ventricular Interdependence on Left Ventricular Diastolic Function in Children With Pulmonary Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, .	2.6	62
121	Cardiac Catheterization in Children with Pulmonary Hypertensive Vascular Disease: Consensus Statement from the Pulmonary Vascular Research Institute, Pediatric and Congenital Heart Disease Task Forces. <i>Pulmonary Circulation</i> , 2016, 6, 118-125.	1.7	49
122	Clinical Classification in Pediatric Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. <i>Pulmonary Circulation</i> , 2016, 6, 302-312.	1.7	24
123	Characterization of CMR-derived haemodynamic data in children with pulmonary arterial hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 18, jew152.	1.2	24
124	Pulmonary Hypertension in Children. <i>Cardiology Clinics</i> , 2016, 34, 451-472.	2.2	43
125	Acute Vasodilator Response in Pediatric Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1312-1323.	2.8	67
126	Growth in children with pulmonary arterial hypertension: a longitudinal retrospective multiregistry study. <i>Lancet Respiratory Medicine</i> , 2016, 4, 281-290.	10.7	20

#	ARTICLE	IF	CITATIONS
127	Hemodynamic response to ketamine in children with pulmonary hypertension. Paediatric Anaesthesia, 2016, 26, 102-108.	1.1	30
128	Persistent Challenges in Pediatric Pulmonary Hypertension. Chest, 2016, 150, 226-236.	0.8	23
129	FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosentan in pUlmonary arterial hypeRtEnsiOn. International Journal of Cardiology, 2016, 202, 52-58.	1.7	37
130	Non-invasive determination by cardiovascular magnetic resonance of right ventricular-vascular coupling in children and adolescents with pulmonary hypertension. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 81.	3.3	31
131	Three-dimensional Echocardiography Enhances Diagnostic Accuracy of Supramitral Ring. Echocardiography, 2015, 32, 1048-1050.	0.9	3
132	Beyond the 6-Minute Walk Test for Assessing Pediatric Pulmonary Hypertension. Chest, 2015, 148, 576-577.	0.8	3
133	Pediatric Pulmonary Hypertension. Circulation, 2015, 132, 2037-2099.	1.6	879
134	Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart, 2015, 101, 1792-1799.	2.9	87
135	Assessment of N-terminal Prohormone B-type Natriuretic Peptide as a Measure of Vascular and Ventricular Function in Pediatric Pulmonary Arterial Hypertension. Pulmonary Circulation, 2015, 5, 658-666.	1.7	10
136	Echocardiographic Estimation of Right Ventricular Stroke Work in Children with Pulmonary Arterial Hypertension: Comparison with Invasive Measurements. Journal of the American Society of Echocardiography, 2015, 28, 1350-1357.	2.8	29
137	Left Ventricular Myocardial Function in Children With Pulmonary Hypertension. Circulation: Cardiovascular Imaging, 2015, 8, .	2.6	45
138	Hospitalizations of Children With Pulmonary Hypertension: Implications for Improving Care. Pediatrics, 2015, 136, 392-393.	2.1	3
139	Abstract 15413: Comparison of Right Ventricular Functional Indices Using Two-dimensional and Three-dimensional Echocardiography to Predict Outcomes in Pediatric Pulmonary Hypertension. Circulation, 2015, 132, .	1.6	0
140	Biomarkers for Pediatric Pulmonary Arterial Hypertension – A Call to Collaborate. Frontiers in Pediatrics, 2014, 2, 7.	1.9	27
141	Echocardiography in Pediatric Pulmonary Hypertension. Frontiers in Pediatrics, 2014, 2, 124.	1.9	99
142	Progress in the diagnosis and management of pulmonary hypertension in children. Current Opinion in Pediatrics, 2014, 26, 527-535.	2.0	14
143	Drug Treatment of Pulmonary Hypertension in Children. Paediatric Drugs, 2014, 16, 43-65.	3.1	51
144	STARTS-2. Circulation, 2014, 129, 1914-1923.	1.6	175

#	ARTICLE	IF	CITATIONS
145	Survival Differences in Pediatric Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2159-2169.	2.8	123
146	RV stroke work in children with pulmonary arterial hypertension: estimation based on invasive haemodynamic assessment and correlation with outcomes. <i>Heart</i> , 2014, 100, 1342-1347.	2.9	33
147	Right Ventricular to Left Ventricular Diameter Ratio at End-Systole in Evaluating Outcomes in Children with Pulmonary Hypertension. <i>Journal of the American Society of Echocardiography</i> , 2014, 27, 172-178.	2.8	84
148	Four- and Seven-Year Outcomes of Patients With Congenital Heart Disease-associated Pulmonary Arterial Hypertension (from the REVEAL Registry). <i>American Journal of Cardiology</i> , 2014, 113, 147-155.	1.6	95
149	Repair of Congenital Heart Disease with Associated Pulmonary Hypertension in Children: What are the Minimal Investigative Procedures? Consensus Statement from the Congenital Heart Disease and Pediatric Task Forces, Pulmonary Vascular Research Institute (PVRI). <i>Pulmonary Circulation</i> , 2014, 4, 330-341.	1.7	44
150	Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. <i>Pediatric Pulmonology</i> , 2013, 48, 27-34.	2.0	86
151	Acute Pulmonary Vasodilator Testing With Inhaled Treprostinil in Children With Pulmonary Arterial Hypertension. <i>Pediatric Cardiology</i> , 2013, 34, 1006-1012.	1.3	23
152	Pediatric Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D117-D126.	2.8	451
153	Children with pulmonary arterial hypertension and prostanoid therapy: Long-term hemodynamics. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 546-552.	0.6	62
154	Ventilatory efficiency slope correlates with functional capacity, outcomes, and disease severity in pediatric patients with pulmonary hypertension. <i>International Journal of Cardiology</i> , 2013, 169, 445-448.	1.7	33
155	Food and Drug Administration (FDA) Postmarket Reported Side Effects and Adverse Events Associated with Pulmonary Hypertension Therapy in Pediatric Patients. <i>Pediatric Cardiology</i> , 2013, 34, 1628-1636.	1.3	29
156	Clinical Trials in Neonates and Children: Report of the Pulmonary Hypertension Academic Research Consortium Pediatric Advisory Committee. <i>Pulmonary Circulation</i> , 2013, 3, 252-266.	1.7	35
157	Evaluation of Circulating Proteins and Hemodynamics Towards Predicting Mortality in Children with Pulmonary Arterial Hypertension. <i>PLoS ONE</i> , 2013, 8, e80235.	2.5	13
158	Circulating Cytokines and Growth Factors in Pediatric Pulmonary Hypertension. <i>Mediators of Inflammation</i> , 2012, 2012, 1-7.	3.0	31
159	Advances in pediatric pulmonary arterial hypertension. <i>Current Opinion in Cardiology</i> , 2012, 27, 70-81.	1.8	26
160	Survival in Childhood Pulmonary Arterial Hypertension. <i>Circulation</i> , 2012, 125, 113-122.	1.6	321
161	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children With Pulmonary Arterial Hypertension. <i>Circulation</i> , 2012, 125, 324-334.	1.6	327
162	Clinical Perspectives with Long-Term Pulsed Inhaled Nitric Oxide for the Treatment of Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2012, 2, 139-147.	1.7	36

#	ARTICLE	IF	CITATIONS
163	Circulating Myeloid-Derived Suppressor Cells Are Increased and Activated in Pulmonary Hypertension. <i>Chest</i> , 2012, 141, 944-952.	0.8	35
164	Clinical features of paediatric pulmonary hypertension: a registry study. <i>Lancet</i> , The, 2012, 379, 537-546.	13.7	441
165	Tissue Doppler Imaging Predicts Adverse Outcome in Children with Idiopathic Pulmonary Arterial Hypertension. <i>Journal of Pediatrics</i> , 2012, 161, 1126-1131.e2.	1.8	47
166	Plasma proteomics of differential outcome to long-term therapy in children with idiopathic pulmonary arterial hypertension. <i>Proteomics - Clinical Applications</i> , 2012, 6, 257-267.	1.6	22
167	Initial Experience With Tadalafil in Pediatric Pulmonary Arterial Hypertension. <i>Pediatric Cardiology</i> , 2012, 33, 683-688.	1.3	99
168	B-type Natriuretic Peptide and Amino-terminal Pro-B-type Natriuretic Peptide in Pediatric Patients with Pulmonary Arterial Hypertension. <i>Congenital Heart Disease</i> , 2012, 7, 259-267.	0.2	50
169	The Pediatric Sildenafil Trial. <i>Advances in Pulmonary Hypertension</i> , 2012, 10, 215-216.	0.1	0
170	Functional Classification of Pulmonary Hypertension in Children: Report from the PVRI Pediatric Taskforce, Panama 2011. <i>Pulmonary Circulation</i> , 2011, 1, 280-285.	1.7	92
171	A Consensus Approach to the Classification of Pediatric Pulmonary Hypertensive Vascular Disease: Report from the PVRI Pediatric Taskforce, Panama 2011. <i>Pulmonary Circulation</i> , 2011, 1, 286-298.	1.7	215
172	Pediatric PH: New Challenges and Perspectives. <i>Advances in Pulmonary Hypertension</i> , 2011, 10, 78-78.	0.1	0
173	Idiopathic pulmonary arterial hypertension in children. , 2011, , 559-571.		0
174	Prostacyclin in the intensive care setting. <i>Pediatric Critical Care Medicine</i> , 2010, 11, S41-S45.	0.5	41
175	Medical Therapy for Pediatric Pulmonary Arterial Hypertension. <i>Journal of Pediatrics</i> , 2010, 157, 528-532.	1.8	40
176	Computational simulation of the pulmonary arteries and its role in the study of pediatric pulmonary hypertension. <i>Progress in Pediatric Cardiology</i> , 2010, 30, 63-69.	0.4	16
177	Long-Term Outcomes in Children With Pulmonary Arterial Hypertension Treated With Bosentan in Real-World Clinical Settings. <i>American Journal of Cardiology</i> , 2010, 106, 1332-1338.	1.6	101
178	A New Era in Medical Management of Severe Pediatric Pulmonary Arterial Hypertension. <i>Nihon Shoni Junkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery</i> , 2010, 26, 206-218.	0.0	1
179	Effects of Long-Term Sildenafil Treatment for Pulmonary Hypertension in Infants with Chronic Lung Disease. <i>Journal of Pediatrics</i> , 2009, 154, 379-384.e2.	1.8	235
180	Sildenafil Increases Systemic Saturation and Reduces Pulmonary Artery Pressure in Patients with Failing Fontan Physiology. <i>Congenital Heart Disease</i> , 2009, 4, 107-111.	0.2	39

#	ARTICLE	IF	CITATIONS
181	Closed-Hub Systems with Protected Connections and the Reduction of Risk of Catheter-Related Bloodstream Infection in Pediatric Patients Receiving Intravenous Prostanoid Therapy for Pulmonary Hypertension. <i>Infection Control and Hospital Epidemiology</i> , 2009, 30, 823-829.	1.8	70
182	Brain Natriuretic Peptide Levels in Managing Pediatric Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2009, 135, 745-751.	0.8	103
183	Chronic Pulmonary Hypertension. , 2009, , 483-505.		0
184	Short- and Long-Term Effects of Inhaled Iloprost Therapy in Children With Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2008, 51, 161-169.	2.8	178
185	Pulmonary vascular input impedance is a combined measure of pulmonary vascular resistance and stiffness and predicts clinical outcomes better than pulmonary vascular resistance alone in pediatric patients with pulmonary hypertension. <i>American Heart Journal</i> , 2008, 155, 166-174.	2.7	142
186	Performance of Cavopulmonary Palliation at Elevated Altitude. <i>Circulation</i> , 2008, 118, S177-81.	1.6	31
187	Transition of Stable Pediatric Patients With Pulmonary Arterial Hypertension from Intravenous Epoprostenol to Intravenous Treprostinil. <i>American Journal of Cardiology</i> , 2007, 99, 696-698.	1.6	78
188	Use of Myocardial Performance Index in Pediatric Patients with Idiopathic Pulmonary Arterial Hypertension. <i>Journal of the American Society of Echocardiography</i> , 2006, 19, 21-27.	2.8	57
189	Utility of cardiopulmonary stress testing in assessing disease severity in children with pulmonary arterial hypertension. <i>American Journal of Cardiology</i> , 2005, 95, 697-699.	1.6	48
190	Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2005, 46, 697-704.	2.8	245
191	High-Altitude Pulmonary Edema in Children With Underlying Cardiopulmonary Disorders and Pulmonary Hypertension Living at Altitude. <i>JAMA Pediatrics</i> , 2004, 158, 1170.	3.0	64
192	Endothelin B Receptor Blockade Attenuates Pulmonary Vasodilation in Oxygen-Ventilated Fetal Lambs. <i>Neonatology</i> , 2004, 86, 155-159.	2.0	15
193	Pulmonary Vascular Effects of Inhaled Nitric Oxide and Oxygen Tension in Bronchopulmonary Dysplasia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 1006-1013.	5.6	181
194	Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. <i>American Journal of Cardiology</i> , 2004, 93, 943-946.	1.6	83
195	Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 372-382.	4.7	299
196	Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2002, 282, L703-L712.	2.9	60
197	Inhaled Nitric Oxide as a Preoperative Test (INOP Test I). <i>Circulation</i> , 2002, 106, .	1.6	97
198	Diagnosis and Treatment of Severe Pediatric Pulmonary Hypertension. <i>Cardiology in Review</i> , 2001, 9, 227-237.	1.4	21